Sammy Farah, Turnstone Biologics CEO
Turnstone Biologics turns to public investors to fund TIL therapies in IPO filing
Solid tumor biotech Turnstone Biologics has filed for an IPO in a bid to fund its early-stage cell therapy clinical trials after losing major deals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
